Company Focus
argenx
Latest argenx News
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Related News
Insights
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.
Latest News & Features of interest to argenx
Pharmaceutical
Texas-based Lexicon Pharmaceuticals has announced that, following a strategic review of the company’s commercial and pipeline programs, it will refocus resources across the portfolio and cut jobs. 14 August 2024
Biotechnology
US oncology focused biotech Syros Pharmaceuticals announced that it will discontinue enrollment in the SELECT-AML-1 Phase II clinical trial. 14 August 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
Biosimilars
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Biotechnology
CRISPR genome-editing biopharma company Caribou Biosciences has announced the appointment of Tina Albertson as chief medical officer (CMO). 13 August 2024
Biotechnology
Octapharma announced the results from the Phase III (LEX-209) study on the efficacy and safety of Balfaxar (prothrombin complex concentrate, human-lans) have been published by the American peer-reviewed journal JAMA Network Open. 13 August 2024
Biotechnology
Shares in Actinogen Medical, an Australian biotech developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol, closed 58% lower on Monday. 13 August 2024
Pharmaceutical
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
Pharmaceutical
Swiss drugmaker Santhera Pharmaceuticals today announced the closing of two financing agreements that provided the company with gross funding totaling around 69 million francs ($80.2 million). 13 August 2024
Biotechnology
Australian biotech CSL Limited today reported revenue of A$14.8 billion (US$9.7 billion) for the 12 months ended June 30, 2024. 13 August 2024
Latest In Brief for argenx
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Latest Relevant Ones To Watch News
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
12 November 2024
30 October 2024
26 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze